Eli Lilly grants one patient access to obesity drug candidate via FDA program

Eli Lilly and the Food and Drug Administration permitted one patient to receive the company's experimental obesity drug retatrutide under the agency's compassionate-use program. The arrangement was reported in coverage of the company's development plans for the candidate.

Podcast discussion covers additional topics The same report examined increased merger-and-acquisition activity among drugmakers and Eli Lilly's evaluation of a potential hair-loss treatment. It also addressed recent Food and Drug Administration actions concerning rare-disease medicines. Listeners were directed to separate articles for further details on each subject.